

MYRIAD GENETICS INC  
Form 8-K  
March 25, 2005

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 24, 2005**

**MYRIAD GENETICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other  
jurisdiction of  
incorporation)

**0-26642**  
(Commission File Number)

**87-0494517**  
(IRS Employer  
Identification No.)

**320 Wakara Way**

**Salt Lake City, Utah 84108**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(801) 584-3600**

**Not Applicable**

(Former name or former address, if changed since last report)

## Edgar Filing: MYRIAD GENETICS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**ITEM 3.01 Notice of Failure to Satisfy a Continued Listing Rule or Standard**

On March 23, 2005 Myriad Genetics, Inc. (the Company) notified the Nasdaq Stock Market ( Nasdaq ) that Dale A. Stringfellow, director and member of the Company s Audit Committee, had passed away on March 18, 2005 due to complications from cancer, and hence, the Company would no longer comply with Nasdaq s audit committee requirements. Under Marketplace Rule 4350, audit committees must consist of at least three independent directors. By letter dated March 24, 2005, Nasdaq acknowledged the Company s notice and confirmed that the Company would be provided a cure period until the earlier of the Company s next annual shareholders meeting or March 18, 2006 in order to regain compliance. The Company intends to appoint a qualified successor to the Company s Audit Committee so as to be in compliance with Marketplace Rule 4350 within the cure period.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MYRIAD GENETICS, INC.**

Date: March 25, 2005

By: */s/ Peter D. Meldrum*  
Peter D. Meldrum  
President and Chief Executive Officer

---